FIP1L1 is a core component of the cleavage and polyadenylation specificity factor (CPSF) complex that mediates pre-mRNA 3'-end formation through recognition of the AAUAAA signal sequence and U-rich RNA elements flanking the poly(A) site. The protein facilitates interactions between poly(A) polymerase and other CPSF complex members, thereby stimulating poly(A) addition and mRNA cleavage at the 3' end. Beyond its canonical role in mRNA processing, FIP1L1 has significant disease relevance as a fusion partner with PDGFRA. The FIP1L1-PDGFRA fusion gene, generated by interstitial chr4 deletion on 4q12, is a pathogenic driver of hypereosinophilic syndrome (HES) and chr4 eosinophilic leukemia (CEL) 12. This fusion creates a constitutively active tyrosine kinase that promotes clonal hematopoietic stem cell expansion with eosinophilic differentiation, often accompanied by systemic mastocytosis and multi-organ eosinophil infiltration 2. Clinically, FIP1L1-PDGFRA-positive HES represents an important disease subtype with profound therapeutic implications. Patients with this fusion demonstrate exceptional responsiveness to imatinib mesylate (88% efficacy), a tyrosine kinase inhibitor, compared to only 23% response in FIP1L1-PDGFRA-negative HES patients 3. Recognition of FIP1L1-PDGFRA status is therefore essential for appropriate patient stratification and personalized treatment selection 4.